- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Sep 16, 2022
Highlights
- Market Cap
- $10.90M
- Enterprise Value
- $9.69M
- EPS (TTM)
- -$0.46
- Total Revenue (TTM)
- $275.58K
- Gross Profit (TTM)
- -$950.31K
- EBITDA (TTM)
- -$8.37M
- Year Range
- $0.31 - $2.00
- ROA (TTM)
- -225.48%
- ROE (TTM)
- -288.63%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NXL Performance Chart
Nexalin Technology Inc. (NXL) is down 1.4% since the beginning of the year. At $1 per share, NXL is trading 72.5% below its 52-week high of $2.
Loading charts...
Returns By Period
Nexalin Technology Inc. (NXL) has returned -1.43% so far this year and -54.92% over the past 12 months.
Nexalin Technology Inc.
- 1D
- -4.60%
- 1M
- 44.62%
- YTD
- -1.43%
- 6M
- -43.30%
- 1Y
- -54.92%
- 3Y*
- -14.82%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
NXL Monthly Returns History
Based on dividend-adjusted daily data since Sep 16, 2022, NXL's average daily return is +0.32%, while the average monthly return is +11.20%. At this rate, an investment would double in approximately 0.5 years.
Historically, 41% of months were positive and 59% were negative. The best month was Mar 2024 with a return of +351.3%, while the worst month was Dec 2022 at -68.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NXL closed higher 43% of trading days. The best single day was Jun 13, 2024 with a return of +125.1%, while the worst single day was Jun 28, 2024 at -42.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.15% | -17.54% | -25.89% | 2.01% | 71.69% | -9.84% | -1.43% | ||||||
| 2025 | 5.80% | -7.19% | -28.04% | -6.67% | -34.62% | -16.99% | 1.24% | -4.37% | -4.08% | 63.54% | -28.00% | -48.33% | -79.78% |
| 2024 | -13.56% | -11.35% | 351.32% | 9.29% | -54.25% | 141.43% | -31.95% | -19.90% | -27.39% | 272.25% | 67.87% | -33.97% | 581.82% |
| 2023 | 41.52% | -16.05% | -10.10% | 2.49% | 4.89% | 3.91% | -9.36% | -45.00% | -1.26% | -34.08% | 34.52% | 3.77% | -45.95% |
| 2022 | -52.00% | 36.11% | 59.18% | -67.99% | -66.71% |
Benchmark Metrics
Nexalin Technology Inc. has an annualized alpha of 70.81%, beta of 1.34, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since September 19, 2022.
- This stock participated in 300.09% of S&P 500 Index downside but only 256.65% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 70.81%
- Beta
- 1.34
- R²
- 0.02
- Upside Capture
- 256.65%
- Downside Capture
- 300.09%
Return for Risk
Risk / Return Rank
NXL ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nexalin Technology Inc. (NXL) and compare them to S&P 500 Index.
| NXL | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.38 | 2.39 | -2.77 |
Sortino ratioReturn per unit of downside risk | 0.07 | 3.25 | -3.19 |
Omega ratioGain probability vs. loss probability | 1.01 | 1.43 | -0.43 |
Calmar ratioReturn relative to maximum drawdown | -0.67 | 3.11 | -3.78 |
Martin ratioReturn relative to average drawdown | -1.01 | 14.38 | -15.39 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nexalin Technology Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nexalin Technology Inc. was 92.64%, occurring on May 19, 2026. The portfolio has not yet recovered.
The current Nexalin Technology Inc. drawdown is 87.39%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -92.64%May 2026 | 1y 5mo | — | 1y 5moDec 2024 - now |
2023 bear market2023 | -88.07%Oct 2023 | 10mo 26d | 5mo 11d | 1y 4moDec 2022 - Apr 2024 |
2024 bear market2024 | -78.95%Oct 2024 | 3mo 13d | 23d | 4mo 6dJun 2024 - Nov 2024 |
2024 bear market2024 | -78.63%Jun 2024 | 2mo 10d | 15d | 2mo 25dApr 2024 - Jun 2024 |
Bear market2022 | -52.00%Sep 2022 | 11d | 1mo 26d | 2mo 7dSep 2022 - Nov 2022 |
Drawdown Indicators
| NXL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.64% | -56.78% | -35.86% |
Max Drawdown (1Y)Largest decline over 1 year | -82.74% | -9.10% | -73.64% |
Max Drawdown (3Y)Largest decline over 3 years | -92.64% | -18.90% | -73.74% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.39% | 0.00% | -87.39% |
Average DrawdownAverage peak-to-trough decline | -64.28% | -10.72% | -53.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.37% | 1.97% | +52.40% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nexalin Technology Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nexalin Technology Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NXL relative to other companies in the Medical Devices industry. Currently, NXL has a P/S ratio of 35.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NXL in comparison with other companies in the Medical Devices industry. Currently, NXL has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NXL
Add Nexalin Technology Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NXL